Updated Treatment Algorithm of Pulmonary Arterial Hypertension

被引:516
作者
Galie, Nazzareno [1 ]
Corris, Paul A. [2 ,3 ]
Frost, Adaani [4 ]
Girgis, Reda E. [5 ]
Granton, John [6 ]
Jing, Zhi Cheng [7 ,8 ,9 ]
Klepetko, Walter [10 ]
McGoon, Michael D. [11 ]
McLaughlin, Vallerie V. [12 ]
Preston, Ioana R. [13 ]
Rubin, Lewis J. [14 ]
Sandoval, Julio [15 ]
Seeger, Werner [16 ]
Keogh, Anne [17 ]
机构
[1] Bologna Univ Hosp, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy
[2] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
[6] Univ Toronto, Div Respirol, Toronto, ON, Canada
[7] Peking Union Med Coll, Fu Wai Hosp, Beijing 100021, Peoples R China
[8] Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Beijing 100021, Peoples R China
[9] Chinese Acad Med Sci, Beijing 100730, Peoples R China
[10] Med Univ Vienna, Vienna Gen Hosp, Dept Thorac Surg, Vienna, Austria
[11] Mayo Clin, Rochester, MN USA
[12] Univ Michigan, Ann Arbor, MI 48109 USA
[13] Tufts Univ, Sch Med, Tufts Med Ctr, Pulm Crit Care & Sleep Div, Boston, MA 02111 USA
[14] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[15] Natl Inst Cardiol Mexico, Mexico City, DF, Mexico
[16] Univ Giessen & Marburg Lung Ctr, Max Planck Inst Heart & Lung Res, Giessen, Germany
[17] St Vincents Hosp, Heart Transplant Unit, Sydney, NSW 2010, Australia
关键词
endothelin receptor antagonists; guanylate cyclase stimulators; hypertension; pulmonary; lung transplantation; phosphodiesterase type-5 inhibitors; prostanoids; CONTINUOUS INTRAVENOUS EPOPROSTENOL; HEART-LUNG TRANSPLANTATION; SURROGATE END-POINTS; QUALITY-OF-LIFE; DOUBLE-BLIND; COMBINATION THERAPY; INHALED ILOPROST; INTERNATIONAL-SOCIETY; EISENMENGER-SYNDROME; AMBRISENTAN THERAPY;
D O I
10.1016/j.jacc.2013.10.031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes different types of recommendations with varying degrees of scientific evidence. In addition, the algorithm is required to be comprehensive but not too complex, informative yet simple and straightforward. The type of information in the treatment algorithm are heterogeneous including clinical, hemodynamic, medical, interventional, pharmacological and regulatory recommendations. Stakeholders (or users) including physicians from various specialties and with variable expertise in PAH, nurses, patients and patients' associations, healthcare providers, regulatory agencies and industry are often interested in the PAH treatment algorithm for different reasons. These are the considerable challenges faced when proposing appropriate updates to the current evidence-based treatment algorithm. The current treatment algorithm may be divided into 3 main areas: 1) general measures, supportive therapy, referral strategy, acute vasoreactivity testing and chronic treatment with calcium channel blockers; 2) initial therapy with approved PAH drugs; and 3) clinical response to the initial therapy, combination therapy, balloon atrial septostomy, and lung transplantation. All three sections will be revisited highlighting information newly available in the past 5 years and proposing updates where appropriate. The European Society of Cardiology grades of recommendation and levels of evidence will be adopted to rank the proposed treatments. (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:D60 / D72
页数:13
相关论文
共 86 条
[41]   Safety and efficacy of exercise training in various forms of pulmonary hypertension [J].
Gruenig, Ekkehard ;
Lichtblau, Mona ;
Ehlken, Nicola ;
Ghofrani, Hossein A. ;
Reichenberger, Frank ;
Staehler, Gerd ;
Halank, Michael ;
Fischer, Christine ;
Seyfarthe, Hans-Juergen ;
Klose, Hans ;
Meyer, Andreas ;
Sorichter, Stephan ;
Wilkens, Heinrike ;
Rosenkranz, Stephan ;
Opitz, Christian ;
Leuchte, Hanno ;
Karger, Gabriele ;
Speich, Rudolf ;
Nagel, Christian .
EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) :84-92
[42]   Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension [J].
Gruenig, Ekkehard ;
Ehlken, Nicola ;
Ghofrani, Ardeschir ;
Staehler, Gerd ;
Meyer, F. Joachim ;
Juenger, Jana ;
Opitz, Christian F. ;
Klose, Hans ;
Wilkens, Heinrike ;
Rosenkranz, Stephan ;
Olschewski, Horst ;
Halank, Michael .
RESPIRATION, 2011, 81 (05) :394-401
[43]   Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension [J].
Higenbottam, T ;
Butt, AY ;
McMahon, A ;
Westerbeck, R ;
Sharples, L .
HEART, 1998, 80 (02) :151-155
[44]   Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial [J].
Hiremath, Jagdish ;
Thanikachalam, Sadagopa ;
Parikh, Keyur ;
Shanmugasundaram, Somasundaram ;
Bangera, Sudhakar ;
Shapiro, Leland ;
Pott, Gregory B. ;
Vnencak-Jones, Cindy L. ;
Arneson, Carl ;
Wade, Michael ;
White, R. James .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (02) :137-149
[45]   Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension [J].
Hoeper, M. M. ;
Leuchte, H. ;
Halank, M. ;
Wilkens, H. ;
Meyer, F. J. ;
Seyfarth, H. J. ;
Wensel, R. ;
Ripken, F. ;
Bremer, H. ;
Kluge, S. ;
Hoeffken, G. ;
Behr, J. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (04) :691-694
[46]   Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension Results of the Randomized IMPRES Study [J].
Hoeper, Marius M. ;
Barst, Robyn J. ;
Bourge, Robert C. ;
Feldman, Jeremy ;
Frost, Adaani E. ;
Galie, Nazzareno ;
Angel Gomez-Sanchez, Miguel ;
Grimminger, Friedrich ;
Gruenig, Ekkehard ;
Hassoun, Paul M. ;
Morrell, Nicholas W. ;
Peacock, Andrew J. ;
Satoh, Toru ;
Simonneau, Gerald ;
Tapson, Victor F. ;
Torres, Fernando ;
Lawrence, David ;
Quinn, Deborah A. ;
Ghofrani, Hossein-Ardeschir .
CIRCULATION, 2013, 127 (10) :1128-+
[47]   Combination of bosentan with epoprostenol in pulmonary arterial hypertension:: BREATHE-2 [J].
Humbert, M ;
Barst, RJ ;
Robbins, IM ;
Channick, RN ;
Galié, N ;
Boonstra, A ;
Rubin, LJ ;
Horn, EM ;
Manes, A ;
Simonneau, G .
EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (03) :353-359
[48]   Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial [J].
Iversen, Kasper ;
Jensen, Annette S. ;
Jensen, Tim V. ;
Vejlstrup, Niels G. ;
Sondergaard, Lars .
EUROPEAN HEART JOURNAL, 2010, 31 (09) :1124-1131
[49]   Pregnancy outcomes in pulmonary arterial hypertension in the modern management era [J].
Jais, Xavier ;
Olsson, Karen M. ;
Barbera, Joan A. ;
Blanco, Isabel ;
Torbicki, Adam ;
Peacock, Andrew ;
Vizza, C. Dario ;
Macdonald, Peter ;
Humbert, Marc ;
Hoeper, Marius M. .
EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (04) :881-885
[50]   Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension [J].
Jing, Z-C. ;
Jiang, X. ;
Han, Z-Y. ;
Xu, X-Q. ;
Wang, Y. ;
Wu, Y. ;
Lv, H. ;
Ma, C-R. ;
Yang, Y-J. ;
Pu, J-L. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (06) :1354-1360